Smita Joshi, Devasena Anantharaman, Richard Muwonge, Neerja Bhatla, Gitika Panicker, Julia Butt, Usha Rani Reddy Poli, Sylla G Malvi, Pulikkottil O Esmy, Eric Lucas, Yogesh Verma, Anand Shah, Eric Zomawia, Sharmila Pimple, Kasturi Jayant, Sanjay Hingmire, Aruna Chiwate, Uma Divate, Shachi Vashist, Gauravi Mishra, Radhika Jadhav, Maqsood Siddiqi, Subha Sankaran, Thiraviam Pillai Rameshwari Ammal Kannan, Purnima Kartha, Surendra S Shastri, Catherine Sauvaget, M Radhakrishna Pillai, Tim Waterboer, Martin Müller, Peter Sehr, Elizabeth R Unger, Rengaswamy Sankaranarayanan, Partha Basu
BACKGROUND: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10 years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women...
November 26, 2022: Vaccine